Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases

K Ibler; Hans Thorhauge Dam; R Gniadecki; Knud Kragballe; G B E Jemec; T Agner

doi:10.1111/j.1468-3083.2009.03202.x

Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases

K Ibler, Hans Thorhauge Dam, R Gniadecki, Knud Kragballe, G B E Jemec, T Agner

24 Citationer (Scopus)

Abstract

Background Efalizumab is a recombinant humanized murine monoclonal antibody against CD11a, approved for the treatment of plaque psoriasis. However, recent reports suggest that it also may be effective in the treatment of severe atopic dermatitis (AD). Objective To evaluate the clinical effect of efalizumab in AD. Methods A systematic retrospective study of the medical files of patients treated with efalizumab for AD in Danish dermatology departments. Positive outcome was defined as improvement of the disease registered in the patient's file over a period exceeding 6 months. Results Two of eleven patients had a positive outcome. Nine patients stopped treatment due to progression of AD or lack of effect. Limitations Retrospective study. Conclusions Only a minority of patients with severe AD responded to efalizumab treatment in a standard dose.

Originalsprog	Engelsk
Tidsskrift	Journal of the European Academy of Dermatology and Venereology
Vol/bind	24
Udgave nummer	7
Sider (fra-til)	837-9
Antal sider	3
ISSN	0926-9959
DOI	https://doi.org/10.1111/j.1468-3083.2009.03202.x
Status	Udgivet - 1 jul. 2010

Adgang til dokumentet

10.1111/j.1468-3083.2009.03202.x

Citationsformater

@article{93cd0837afa043089451b0b52382b44d,

title = "Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases",

abstract = "Background Efalizumab is a recombinant humanized murine monoclonal antibody against CD11a, approved for the treatment of plaque psoriasis. However, recent reports suggest that it also may be effective in the treatment of severe atopic dermatitis (AD). Objective To evaluate the clinical effect of efalizumab in AD. Methods A systematic retrospective study of the medical files of patients treated with efalizumab for AD in Danish dermatology departments. Positive outcome was defined as improvement of the disease registered in the patient's file over a period exceeding 6 months. Results Two of eleven patients had a positive outcome. Nine patients stopped treatment due to progression of AD or lack of effect. Limitations Retrospective study. Conclusions Only a minority of patients with severe AD responded to efalizumab treatment in a standard dose.",

author = "K Ibler and Dam, {Hans Thorhauge} and R Gniadecki and Knud Kragballe and Jemec, {G B E} and T Agner",

year = "2010",

month = jul,

day = "1",

doi = "10.1111/j.1468-3083.2009.03202.x",

language = "English",

volume = "24",

pages = "837--9",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "Elsevier",

number = "7",

}

TY - JOUR

T1 - Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases

AU - Ibler, K

AU - Dam, Hans Thorhauge

AU - Gniadecki, R

AU - Kragballe, Knud

AU - Jemec, G B E

AU - Agner, T

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Background Efalizumab is a recombinant humanized murine monoclonal antibody against CD11a, approved for the treatment of plaque psoriasis. However, recent reports suggest that it also may be effective in the treatment of severe atopic dermatitis (AD). Objective To evaluate the clinical effect of efalizumab in AD. Methods A systematic retrospective study of the medical files of patients treated with efalizumab for AD in Danish dermatology departments. Positive outcome was defined as improvement of the disease registered in the patient's file over a period exceeding 6 months. Results Two of eleven patients had a positive outcome. Nine patients stopped treatment due to progression of AD or lack of effect. Limitations Retrospective study. Conclusions Only a minority of patients with severe AD responded to efalizumab treatment in a standard dose.

AB - Background Efalizumab is a recombinant humanized murine monoclonal antibody against CD11a, approved for the treatment of plaque psoriasis. However, recent reports suggest that it also may be effective in the treatment of severe atopic dermatitis (AD). Objective To evaluate the clinical effect of efalizumab in AD. Methods A systematic retrospective study of the medical files of patients treated with efalizumab for AD in Danish dermatology departments. Positive outcome was defined as improvement of the disease registered in the patient's file over a period exceeding 6 months. Results Two of eleven patients had a positive outcome. Nine patients stopped treatment due to progression of AD or lack of effect. Limitations Retrospective study. Conclusions Only a minority of patients with severe AD responded to efalizumab treatment in a standard dose.

U2 - 10.1111/j.1468-3083.2009.03202.x

DO - 10.1111/j.1468-3083.2009.03202.x

M3 - Journal article

SN - 0926-9959

VL - 24

SP - 837

EP - 839

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

IS - 7

ER -

Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater